Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind …
S Danese, S Vermeire, W Zhou, AL Pangan… - The lancet, 2022 - thelancet.com
Background There is a great unmet need for advanced therapies that provide rapid, robust,
and sustained disease control for patients with ulcerative colitis. We assessed the efficacy …
and sustained disease control for patients with ulcerative colitis. We assessed the efficacy …
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
…, MA Brown, V Arora, AL Pangan - Annals of the …, 2013 - ard.bmj.com
Purpose To evaluate the efficacy and safety of adalimumab in patients with non-radiographic
axial spondyloarthritis (nr-axSpA). Methods Patients fulfilled Assessment of …
axial spondyloarthritis (nr-axSpA). Methods Patients fulfilled Assessment of …
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
…, GR Burmester, JD Kent, AL Pangan… - Annals of the …, 2006 - ard.bmj.com
Objective: To assess the safety of adalimumab in global clinical trials and postmarketing
surveillance among patients with rheumatoid arthritis (RA). Methods: Safety data for …
surveillance among patients with rheumatoid arthritis (RA). Methods: Safety data for …
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a …
…, Y Zhou, MEF Mohamed, S Meerwein, AL Pangan - The Lancet, 2018 - thelancet.com
Background Phase 2 studies with upadacitinib, a selective Janus kinase 1 (JAK1) inhibitor,
have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. …
have shown safety and efficacy in the treatment of patients with active rheumatoid arthritis. …
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs …
…, L Bessette, Y Li, Y Zhou, AA Othman, AL Pangan… - The Lancet, 2018 - thelancet.com
Background Upadacitinib is a selective inhibitor of Janus kinase 1 and was efficacious in
phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. We aimed to assess …
phase 2 studies in patients with moderate-to-severe rheumatoid arthritis. We aimed to assess …
Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double‐blind …
R Fleischmann, AL Pangan, IH Song… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy, including capacity for inhibition of radiographic
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or …
progression, and safety of upadacitinib, a JAK 1‐selective inhibitor, as compared to placebo or …
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two …
…, HD Teixeira, EL Simpson, KA Papp, AL Pangan… - The Lancet, 2021 - thelancet.com
Background Upadacitinib is an oral Janus kinase (JAK) inhibitor with greater inhibitory
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and …
potency for JAK1 than JAK2, JAK3, and tyrosine kinase 2. We aimed to assess the efficacy and …
[HTML][HTML] Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
E Guttman-Yassky, D Thaçi, AL Pangan… - Journal of Allergy and …, 2020 - Elsevier
Background Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic
skin lesions. Objective We sought to evaluate the safety and efficacy of multiple doses of …
skin lesions. Objective We sought to evaluate the safety and efficacy of multiple doses of …
[HTML][HTML] Trial of upadacitinib and adalimumab for psoriatic arthritis
…, L Chen, P Zueger, J Liu, AL Pangan… - … England Journal of …, 2021 - Mass Medical Soc
Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic
arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis …
arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis …
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised …
Background Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy
in combination with stable background conventional synthetic disease-modifying …
in combination with stable background conventional synthetic disease-modifying …